Dengxi Wu

Title: Innovations of Dengxi Wu in Biotech

Introduction

Dengxi Wu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of polypeptides and their applications in glucose regulation. With a total of 3 patents, his work has the potential to impact diabetes treatment and management.

Latest Patents

One of his latest patents is titled "Method of producing insulinotropic GLP-1 (7-36) polypeptide and/or GLP-1 analogs." This invention discloses a method for producing polypeptides, including insulinotropic GLP-1 (7-36) polypeptide and/or GLP-1 analogs, by ligating genes in a tandem manner. The method allows for the expression of 1 to 32 copies of GLP-1 (7-36) and/or GLP-1 analog genes in tandem, leading to the production of recombinant polypeptides on a large scale at a significantly reduced cost.

Another notable patent is "Derivatives of the insulinotropic peptide exendin-4 and methods of production thereof." This invention focuses on developing novel exendin-4 derivatives that exhibit advantageous glucose-regulatory properties. The methods described simplify the production process of these derivatives, thereby lowering production costs.

Career Highlights

Dengxi Wu has worked with notable companies such as Shanghai Huayi Bio-lab Co., Ltd. and Shanghai Huayi Biotech Lab. His experience in these organizations has contributed to his expertise in biotechnology and innovation.

Collaborations

Dengxi Wu has collaborated with several professionals in his field, including Yukun Sun and Zhiyong Zhu. These collaborations have likely enhanced his research and development efforts.

Conclusion

Dengxi Wu's innovative work in biotechnology, particularly in the production of insulinotropic polypeptides and derivatives, showcases his significant contributions to the field. His patents reflect a commitment to advancing medical science and improving treatment options for diabetes.